Open Access
Aponermin: First Approval
Тип публикации: Journal Article
Дата публикации: 2024-03-05
scimago Q1
wos Q1
БС1
SJR: 3.362
CiteScore: 26.2
Impact factor: 14.4
ISSN: 00126667, 11791950
PubMed ID:
38441805
Pharmacology (medical)
Краткое описание
Aponermin (沙艾特) is a recombinant circularly permuted human tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) developed by Beijing Sunbio Biotech (a wholly owned subsidiary of Wuhan Hiteck Biological Pharma CO., LTD) for the treatment of multiple myeloma. Aponermin binds to and activates the death receptors 4 and/or 5 on tumour cells, triggering intracellular caspase reactions and inducing apoptosis, thereby exerting antitumor effects. In November 2023, aponermin in combination with thalidomide and dexamethasone received its first approval in China for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. This article summarizes the milestones in the development of aponermin leading to this first approval for relapsed or refractory multiple myeloma.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
3
|
|
|
Scientific Reports
3 публикации, 17.65%
|
|
|
International Journal of Molecular Sciences
1 публикация, 5.88%
|
|
|
RSC Medicinal Chemistry
1 публикация, 5.88%
|
|
|
Nature Reviews Drug Discovery
1 публикация, 5.88%
|
|
|
Antibody Therapeutics
1 публикация, 5.88%
|
|
|
Molecular Pharmaceutics
1 публикация, 5.88%
|
|
|
Russian Chemical Reviews
1 публикация, 5.88%
|
|
|
The Innovation
1 публикация, 5.88%
|
|
|
Blood Science
1 публикация, 5.88%
|
|
|
International Journal of Biological Macromolecules
1 публикация, 5.88%
|
|
|
Journal of Controlled Release
1 публикация, 5.88%
|
|
|
Medical Oncology
1 публикация, 5.88%
|
|
|
Biomaterials Science
1 публикация, 5.88%
|
|
|
1
2
3
|
Издатели
|
1
2
3
4
5
|
|
|
Springer Nature
5 публикаций, 29.41%
|
|
|
Elsevier
4 публикации, 23.53%
|
|
|
Royal Society of Chemistry (RSC)
2 публикации, 11.76%
|
|
|
MDPI
1 публикация, 5.88%
|
|
|
Oxford University Press
1 публикация, 5.88%
|
|
|
American Chemical Society (ACS)
1 публикация, 5.88%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 5.88%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 5.88%
|
|
|
Cold Spring Harbor Laboratory
1 публикация, 5.88%
|
|
|
1
2
3
4
5
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
17
Всего цитирований:
17
Цитирований c 2025:
11
(64.7%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Dhillon S. Aponermin: First Approval // Drugs. 2024. Vol. 84. No. 4. pp. 459-466.
ГОСТ со всеми авторами (до 50)
Скопировать
Dhillon S. Aponermin: First Approval // Drugs. 2024. Vol. 84. No. 4. pp. 459-466.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1007/s40265-024-02004-9
UR - https://doi.org/10.1007/s40265-024-02004-9
TI - Aponermin: First Approval
T2 - Drugs
AU - Dhillon, Sohita
PY - 2024
DA - 2024/03/05
PB - Springer Nature
SP - 459-466
IS - 4
VL - 84
PMID - 38441805
SN - 0012-6667
SN - 1179-1950
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2024_Dhillon,
author = {Sohita Dhillon},
title = {Aponermin: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1007/s40265-024-02004-9},
number = {4},
pages = {459--466},
doi = {10.1007/s40265-024-02004-9}
}
Цитировать
MLA
Скопировать
Dhillon, Sohita. “Aponermin: First Approval.” Drugs, vol. 84, no. 4, Mar. 2024, pp. 459-466. https://doi.org/10.1007/s40265-024-02004-9.